Back to Search
Start Over
Cholesteryl Ester Transfer Protein Inhibitors
- Source :
- Journal of Cardiovascular Pharmacology and Therapeutics. 22:99-104
- Publication Year :
- 2016
- Publisher :
- SAGE Publications, 2016.
-
Abstract
- The cholesteryl ester transfer protein (CETP) is a plasma protein that plays an important role in the transfer of lipids between plasma lipoproteins. The CETP inhibitors have been widely studied as a pharmacologic therapy to target plasma cholesterol in order to reduce the risk of atherosclerotic cardiovascular disease . Using CETP inhibitors as cholesterol modifiers was based on the genetic research that found correlations between CETP activity and cholesterol levels. Although CETP inhibitors are successful at altering targeted cholesterol markers, recent phase 3 outcome trials have shown limited benefit on cardiovascular outcomes when combined with the current standard of care. We discuss the science of CETP inhibition, compare the CETP inhibitors developed (torcetrapib, evacetrapib, dalcetrapib, and anacetrapib), the findings from the CETP inhibitor trials, and the future outlook for CETP inhibitors in cholesterol modification.
- Subjects :
- Pharmacology
biology
Cholesterol
business.industry
Dalcetrapib
Torcetrapib
030204 cardiovascular system & hematology
Blood proteins
carbohydrates (lipids)
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
chemistry
Anacetrapib
Cholesterylester transfer protein
biology.protein
Medicine
lipids (amino acids, peptides, and proteins)
Pharmacology (medical)
030212 general & internal medicine
Cardiology and Cardiovascular Medicine
business
CETP inhibitor
Evacetrapib
Subjects
Details
- ISSN :
- 19404034 and 10742484
- Volume :
- 22
- Database :
- OpenAIRE
- Journal :
- Journal of Cardiovascular Pharmacology and Therapeutics
- Accession number :
- edsair.doi.dedup.....be8b8951853576d4a503db48fbc79bf7
- Full Text :
- https://doi.org/10.1177/1074248416662349